Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roel Verhaak

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Acta Neuropathologica|January 12, 2017
Glioma: experimental models and realityKrissie Lenting, Roel Verhaak, Mark Ter Laan, et al.
Molecular Cancer Therapeutics|May 20, 2016
MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in GlioblastomaShaofang Wu, Shuzhen Wang, Siyuan Zheng, et al.
Molecular Oncology|May 17, 2024
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal locationAsli Küçükosmanoglu, Carolien L van der Borden, Lisanne E A de Boer, et al.
Oncotarget|March 1, 2018
The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selectionAndrea M Muscat, Nicholas C Wong, Katharine J Drummond, et al.
Neuro-Oncology|March 15, 2026
DNA Methylation Profiling Reveals a Novel Subtype Harboring IDH Mutation in H3-altered GliomasMinjie Fu, Yuan Feng, Pin Sun, et al.
Scientific Reports|October 12, 2019
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastomaRohit Sachdeva, Megan Wu, Kevin Johnson, et al.
Oncotarget|March 15, 2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cellsJianwen Dong, Soon Young Park, Nghi Nguyen, et al.
Cell|January 12, 2021
A modular master regulator landscape controls cancer transcriptional identityEvan O Paull, Alvaro Aytes, Sunny J Jones, et al.
Cancer Research|October 18, 2011
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapiesJeonghee Cho, Sandra Pastorino, Qing Zeng, et al.
Journal of the National Cancer Institute|September 10, 2025
Challenges in the return of molecular tumor profiling resultsHeinz-Josef Lenz, David W Craig, Kevin C Johnson, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Acta Neuropathologica|January 12, 2017
Glioma: experimental models and realityKrissie Lenting, Roel Verhaak, Mark Ter Laan, et al.
Molecular Cancer Therapeutics|May 20, 2016
MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in GlioblastomaShaofang Wu, Shuzhen Wang, Siyuan Zheng, et al.
Molecular Oncology|May 17, 2024
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal locationAsli Küçükosmanoglu, Carolien L van der Borden, Lisanne E A de Boer, et al.
Oncotarget|March 1, 2018
The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selectionAndrea M Muscat, Nicholas C Wong, Katharine J Drummond, et al.
Neuro-Oncology|March 15, 2026
DNA Methylation Profiling Reveals a Novel Subtype Harboring IDH Mutation in H3-altered GliomasMinjie Fu, Yuan Feng, Pin Sun, et al.
Scientific Reports|October 12, 2019
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastomaRohit Sachdeva, Megan Wu, Kevin Johnson, et al.
Oncotarget|March 15, 2018
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cellsJianwen Dong, Soon Young Park, Nghi Nguyen, et al.
Cell|January 12, 2021
A modular master regulator landscape controls cancer transcriptional identityEvan O Paull, Alvaro Aytes, Sunny J Jones, et al.
Cancer Research|October 18, 2011
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapiesJeonghee Cho, Sandra Pastorino, Qing Zeng, et al.
Journal of the National Cancer Institute|September 10, 2025
Challenges in the return of molecular tumor profiling resultsHeinz-Josef Lenz, David W Craig, Kevin C Johnson, et al.
Pageof 3